Work

Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4588

Authors: Sujun Han, Feiya Yang, Yong Zhang, Xiongjun Ye, Hongzhe Shi, Bolin Jia, Xingang Bi, Wasilijiang Wahafu, Hongsong Bai, Linjun Hu, Xin Wang, Nianzeng Xing

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanxi Medical University, Shanxi Provincial Cancer Hospital, Cancer Hospital of Huanxing Chaoyang District Beijing

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822276

Cites:

Cited by: 2

Related to: 10